Methylprednisolone
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Methylprednisolone: From Autoimmune and Inflammatory Diseases to Alopecia Areata
One-Sentence Summary
Methylprednisolone is a glucocorticoid originally used for autoimmune and inflammatory conditions, including Crohn disease, adrenocortical insufficiency and acute lymphoblastic leukaemia. The TxGNN model predicts it may be effective for alopecia areata, with 1 clinical trial and 19 publications currently supporting this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Autoimmune disease, Crohn disease, adrenocortical insufficiency, acute lymphoblastic leukaemia, and others (the Singapore licence records contain no indication text) |
| Predicted New Indication | Alopecia areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, methylprednisolone is a potent glucocorticoid. It suppresses T-cell activation and the production of pro-inflammatory cytokines, and its efficacy in autoimmune disease is well established.
Alopecia areata is a T-cell mediated autoimmune attack on hair follicles, with loss of the follicle's immune privilege. High-dose pulse regimens, given orally or intravenously, are used in severe disease to halt this immune attack quickly. This is consistent with the drug's established use in autoimmune conditions.
One limitation is that relapse after withdrawal is common. Steroids do not correct the underlying autoimmune predisposition, so benefit may be temporary.
Other predicted indications, such as alopecia mucinosa, telogen effluvium and folliculitis decalvans, have no clinical trials or literature. Their predictions are computational inferences only and are not evaluated further here.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral mega-pulse methylprednisolone in severe, therapy-resistant alopecia areata, using higher doses and more frequent pulses than earlier regimens. Results and control-arm design should be verified. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32270396 | 2020 | Systematic Review | Dermatol Ther | Cyclosporine with and without systemic corticosteroids in alopecia areata; outcomes vary |
| 28378336 | 2017 | Review | Int J Dermatol | Treatment options for alopecia totalis and universalis, which are difficult to manage; no therapy is FDA-approved |
| 37992355 | 2023 | Review | Dermatol Pract Concept | Efficacy, relapse rates, side effects and prognostic factors of corticosteroid pulse therapy |
| 36461625 | 2023 | Review | Pediatr Dermatol | Dosing regimens and side effects of pulse corticosteroids in children with alopecia areata |
| 9777767 | 1998 | Open prospective study | J Am Acad Dermatol | Pulse methylprednisolone in 45 patients with severe alopecia areata |
| 8274789 | 1993 | Cohort | Dermatology | IV methylprednisolone pulses in 9 patients with recent-onset severe disease; progression stopped in 8 |
| 12746668 | 2003 | Open study | Ann Dermatol Venereol | Monthly repeated IV pulses in 66 patients with severe alopecia areata |
| 25566921 | 2015 | Cohort | Indian J Dermatol Venereol Leprol | IV methylprednisolone pulse therapy in severe alopecia areata |
| 35986630 | 2022 | Retrospective cohort | Dermatol Ther | Methylprednisolone alone versus combined with methotrexate in 26 patients with extensive disease |
| 22426909 | 2012 | Clinical study | Saudi Med J | Oral mega-pulse methylprednisolone for severe therapy-resistant alopecia areata |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04683P | SOLU-MEDROL FOR INJECTION 500 mg/8 ml | Powder for solution for injection | Not stated in the available records |
| SIN14594P | METHYLPREDNISOLONE POWDER FOR SOLUTION FOR INJECTION 500mg | Lyophilised powder for solution for injection | Not stated in the available records |
Both licences are for injectable products, which suits IV pulse therapy. Oral pulse regimens, as used in NCT01167946, would need a separate check of oral product availability.
Safety Considerations
- Disease-based contraindications (knowledge graph): The knowledge graph links methylprednisolone with contraindications in hypertension, congestive heart failure, hyperglycaemia, epilepsy, herpes simplex keratitis, measles, urea cycle disorders (carbamoyl phosphate synthetase I deficiency, citrullinemia, hyperargininemia), and pituitary hormone deficiency conditions. These come from the knowledge graph, not from label text.
- Drug interactions: 100 interactions were recorded; the first 20 reviewed include:
- Major: bupropion, clarithromycin.
- Moderate: antidiabetic drugs (metformin, pioglitazone, acarbose, alogliptin, dapagliflozin, empagliflozin, canagliflozin, saxagliptin, dulaglutide, albiglutide, chlorpropamide), amphotericin B, aprepitant, acetylsalicylic acid, and laxatives (bisacodyl, picosulfuric acid).
- Minor: zinc sulfate.
- Glucose monitoring is particularly relevant given the number of antidiabetic interactions.
Please refer to the package insert for label warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: One completed Phase 4 trial (42 patients) and a substantial body of pulse-therapy literature support use in severe alopecia areata. However, this literature is mostly small open or retrospective studies, and no randomised controlled comparison was identified. Relapse after withdrawal is common, and steroid toxicity limits repeated use. The evidence therefore supports L2 rather than L1.
To proceed, the following is needed:
- Package insert warnings and contraindications, which are currently missing and are required for safety screening
- Detailed mechanism of action data
- Review of NCT01167946 results and its control-arm design
- Confirmation of the approved indications on the two Singapore licences
- Assessment of oral versus IV route availability in Singapore
- A relapse and long-term steroid safety monitoring plan, including blood pressure and glucose checks
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.